VRTX — Vertex Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $121.15bn
- $114.65bn
- $12.00bn
- 99
- 28
- 77
- 77
Annual cashflow statement for Vertex Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 2,342 | 3,322 | 3,620 | -536 | 3,953 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 436 | 595 | 539 | 699 | 1,178 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -105 | 341 | -266 | -515 | -1,199 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 2,644 | 4,130 | 3,537 | -493 | 3,631 |
| Capital Expenditures | -235 | -205 | -258 | -485 | -438 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -106 | -116 | -2,883 | -3,285 | -508 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -341 | -321 | -3,142 | -3,770 | -945 |
| Financing Cash Flow Items | -130 | -169 | -226 | -399 | -366 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -1,478 | -67.7 | -562 | -1,495 | -2,261 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 811 | 3,712 | -140 | -5,800 | 516 |